Short Term Warfarin Therapy for Radiofrequency Catheter Ablation of Atrial Fibrillation

Prospective Randomized Study of Incidence of Thromboembolic and Bleeding Events According to the Period of Warfarin Use Before and After Catheter Ablation of Paroxysmal Atrial Fibrillation in Low Risk Patients

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01991951

Enrollment

520

Registered

2013-11-25

Start date

2013-07-31

Completion date

2017-07-31

Last updated

2013-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

We hypothesized that in patients with low CHADS-VASc score (2 or \< 2), there is no difference in thromboembolic or bleeding events between patients with short term warfarin therapy (2 weeks after catheter ablation) and conventional therapy (3 weeks before and 8 weeks after procedure).

Interventions

DRUGwarfarin

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with paroxysmal atrial fibrillation who underwent radiofrequency catheter ablation * Patients with CHADS-VASc score 2 or less than 2

Exclusion criteria

* Patients who do not consent to the study * Permanent or persistent atrial fibrillation * Patients who have underwent prior catheter ablation for atrial fibrillation * CHADS-VASc score more than 2 * History of stroke * LVEF \<40% * Significant liver or kidney dysfunction * History of major bleeding during warfarin therapy

Design outcomes

Primary

Measure	Time frame
Incidence of thromboembolic and bleeding events during 2 months	2 months after the procedure

Countries

South Korea

Contacts

Primary ContactJaemin Shim, MD

jshim@kumc.or.kr82-10-6776-1195

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026